245 related articles for article (PubMed ID: 26306030)
1. A Bisbenzamidine Phosphonate as a Janus-faced Inhibitor for Trypsin-like Serine Proteases.
Häußler D; Scheidt T; Stirnberg M; Steinmetzer T; Gütschow M
ChemMedChem; 2015 Oct; 10(10):1641-6. PubMed ID: 26306030
[TBL] [Abstract][Full Text] [Related]
2. Evaluation of bisbenzamidines as inhibitors for matriptase-2.
Beckmann AM; Gilberg E; Gattner S; Huang TL; Vanden Eynde JJ; Mayence A; Bajorath J; Stirnberg M; Gütschow M
Bioorg Med Chem Lett; 2016 Aug; 26(15):3741-5. PubMed ID: 27287367
[TBL] [Abstract][Full Text] [Related]
3. Active site mapping of trypsin, thrombin and matriptase-2 by sulfamoyl benzamidines.
Dosa S; Stirnberg M; Lülsdorff V; Häußler D; Maurer E; Gütschow M
Bioorg Med Chem; 2012 Nov; 20(21):6489-505. PubMed ID: 23026080
[TBL] [Abstract][Full Text] [Related]
4. Synthesis and evaluation of diphenyl phosphonate esters as inhibitors of the trypsin-like granzymes A and K and mast cell tryptase.
Jackson DS; Fraser SA; Ni LM; Kam CM; Winkler U; Johnson DA; Froelich CJ; Hudig D; Powers JC
J Med Chem; 1998 Jun; 41(13):2289-301. PubMed ID: 9632362
[TBL] [Abstract][Full Text] [Related]
5. Structure-based approach for the discovery of bis-benzamidines as novel inhibitors of matriptase.
Enyedy IJ; Lee SL; Kuo AH; Dickson RB; Lin CY; Wang S
J Med Chem; 2001 Apr; 44(9):1349-55. PubMed ID: 11311057
[TBL] [Abstract][Full Text] [Related]
6. Limiting the Number of Potential Binding Modes by Introducing Symmetry into Ligands: Structure-Based Design of Inhibitors for Trypsin-Like Serine Proteases.
Furtmann N; Häußler D; Scheidt T; Stirnberg M; Steinmetzer T; Bajorath J; Gütschow M
Chemistry; 2016 Jan; 22(2):610-25. PubMed ID: 26625703
[TBL] [Abstract][Full Text] [Related]
7. Oxyanion-mediated inhibition of serine proteases.
Presnell SR; Patil GS; Mura C; Jude KM; Conley JM; Bertrand JA; Kam CM; Powers JC; Williams LD
Biochemistry; 1998 Dec; 37(48):17068-81. PubMed ID: 9836602
[TBL] [Abstract][Full Text] [Related]
8. Design, synthesis and biological activity of novel rigid amidino-phenylalanine derivatives as inhibitors of thrombin.
Mack H; Pfeiffer T; Hornberger W; Böhm HJ; Höffken HW
J Enzyme Inhib; 1995; 9(1):73-86. PubMed ID: 8568568
[TBL] [Abstract][Full Text] [Related]
9. Inhibition of bovine beta-trypsin, human alpha-thrombin and porcine pancreatic beta-kallikrein-B by 4',6-diamidino-2-phenylindole, 6-amidinoindole and benzamidine: a comparative thermodynamic and X-ray structural study.
Casale E; Collyer C; Ascenzi P; Balliano G; Milla P; Viola F; Fasano M; Menegatti E; Bolognesi M
Biophys Chem; 1995 Mar; 54(1):75-81. PubMed ID: 7703351
[TBL] [Abstract][Full Text] [Related]
10. Inhibition of bovine beta-trypsin, human alpha-thrombin and porcine pancreatic beta-kallikrein-B by benzamidine and its bis-, tris- and tetra-derivatives: thermodynamic and molecular modeling study.
Menegatti E; Ferroni R; Nastruzzi C; Bortolotti F; Scalia S; Amiconi G; Bolognesi M; Coletta M; Onesti S; Fruttero R
Farmaco; 1991 Nov; 46(11):1297-310. PubMed ID: 1811616
[TBL] [Abstract][Full Text] [Related]
11. Selective inhibition of large-to-small surfactant aggregate conversion by serine protease inhibitors of the bis-benzamidine type.
Ruppert C; Pucker C; Markart P; Schmidt R; Grimminger F; Seeger W; Stürzebecher J; Günther A
Am J Respir Cell Mol Biol; 2003 Jan; 28(1):95-102. PubMed ID: 12495937
[TBL] [Abstract][Full Text] [Related]
12. Phosphono Bisbenzguanidines as Irreversible Dipeptidomimetic Inhibitors and Activity-Based Probes of Matriptase-2.
Häußler D; Mangold M; Furtmann N; Braune A; Blaut M; Bajorath J; Stirnberg M; Gütschow M
Chemistry; 2016 Jun; 22(25):8525-35. PubMed ID: 27214780
[TBL] [Abstract][Full Text] [Related]
13. Inhibition of human mast cell tryptase by benzamidine derivatives.
Stürzebecher J; Prasa D; Sommerhoff CP
Biol Chem Hoppe Seyler; 1992 Oct; 373(10):1025-30. PubMed ID: 1418674
[TBL] [Abstract][Full Text] [Related]
14. Spontaneous inactivation of human tryptase involves conformational changes consistent with conversion of the active site to a zymogen-like structure.
Selwood T; McCaslin DR; Schechter NM
Biochemistry; 1998 Sep; 37(38):13174-83. PubMed ID: 9748324
[TBL] [Abstract][Full Text] [Related]
15. Changing the selectivity profile - from substrate analog inhibitors of thrombin and factor Xa to potent matriptase inhibitors.
Maiwald A; Hammami M; Wagner S; Heine A; Klebe G; Steinmetzer T
J Enzyme Inhib Med Chem; 2016; 31(sup1):89-97. PubMed ID: 27168215
[TBL] [Abstract][Full Text] [Related]
16. Inhibition of four human serine proteases by substituted benzamidines.
Andrews JM; Roman DP; Bing DH
J Med Chem; 1978 Dec; 21(12):1202-7. PubMed ID: 152812
[TBL] [Abstract][Full Text] [Related]
17. Low molecular weight activated protein C inhibitors as a potential treatment for hemophilic disorders.
De Nanteuil G; Gloanec P; Béguin S; Giesen PL; Hemker HC; Mennecier P; Rupin A; Verbeuren TJ
J Med Chem; 2006 Aug; 49(17):5047-50. PubMed ID: 16913694
[TBL] [Abstract][Full Text] [Related]
18. Structure-based discovery of small molecule hepsin and HGFA protease inhibitors: Evaluation of potency and selectivity derived from distinct binding pockets.
Franco FM; Jones DE; Harris PK; Han Z; Wildman SA; Jarvis CM; Janetka JW
Bioorg Med Chem; 2015 May; 23(10):2328-43. PubMed ID: 25882520
[TBL] [Abstract][Full Text] [Related]
19. A comprehensive study on the mechanism of inhibition of serine proteases by benzamidines based on quantitative structure-activity relationship studies.
Gupta SP; Handa A; Shewade DG
Arzneimittelforschung; 1987 Jan; 37(1):47-50. PubMed ID: 2952126
[TBL] [Abstract][Full Text] [Related]
20. Peptidic phosphonylating agents as irreversible inhibitors of serine proteases and models of the tetrahedral intermediates.
Sampson NS; Bartlett PA
Biochemistry; 1991 Feb; 30(8):2255-63. PubMed ID: 1998684
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
